Cancer News and Research

Latest Cancer News and Research

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

M. D. Anderson Cancer Center recommends colonoscopy screening to reduce risk of colon cancer

M. D. Anderson Cancer Center are encouraging men and women to learn more about colon polyps and how they affect a person's risks for cancer.

11 Mar 2010

Collaborative center established to reduce obesity-related deaths in African-American and Latino communities

A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.

11 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Pro-Pharmaceuticals announces closing of $335,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.

11 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

NeoMed invests in CytoCore

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that NeoMed has made an investment in CytoCore Inc.

11 Mar 2010

USPTO issues patent related to Seattle Genetics' ADC technology

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

11 Mar 2010

Evaluating true toxicity of drugs: Changes in collecting and reporting adverse symptom information needed

A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.

11 Mar 2010

Whole genome sequencing of entire family beneficial

The Institute for Systems Biology (ISB) has analyzed the first whole genome sequences of a human family of four. The findings of a project funded through a partnership between ISB and the University of Luxembourg was published online today by Science on its Science Express website. It demonstrates the benefit of sequencing entire families, including lowering error rates, identifying rare genetic variants and identifying disease-linked genes.

11 Mar 2010

WHO FCTC celebrates fifth anniversary

A ceremony marking the fifth anniversary of the entry into force of the WHO Framework Convention on Tobacco Control (FCTC) was held today in the Geneva headquarters of the World Health Organization.

11 Mar 2010

InvestorSoup.com announces investment report featuring Exact Sciences

InvestorSoup.com announces an investment report featuring Exact Sciences Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Senetek closes Security Purchase Agreement with DMRJ

Senetek PLC today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New York, New York.

11 Mar 2010

ADI’s 20-bit DAC enables superior image clarity, resolution, and contrast in medical imaging systems

MRI (magnetic resonance imaging) scans provide extraordinarily clear images of the human body and are commonly used to diagnose a wide range of illnesses and injuries, such as Alzheimer’s disease, cancerous tumors, and torn ligaments. Analog Devices, Inc., the leading provider of data conversion technology and longtime collaborator with the medical imaging industry, today introduced a breakthrough in data conversion that gives clinicians and radiologists the superior image clarity they need to see smaller anatomical structures and abnormalities, such as breast cancer cells, than ever before.

11 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010